Jury Favors Merck Over Gilead In Hepatitis C Drug Patent Dispute A federal jury favored Merck & Co. over Gilead Sciences Inc. in a high-profile lawsuit involving patents for new hepatitis C drugs. Merck sued Gilead for using sofosbuvir in hepatitis drugs Sovaldi and Harvoni. by Rhodi Lee
Healthy Living/Wellness Gilead Pricing Strategy For Hepatitis C Drug Sovaldi Focused on Maximizing Profits Not Patients: Report by Katrina Pascual
Healthy Living/Wellness FDA Embroiled In Legal Battle Over Gilead Hepatitis C Drug Trial by Jill Arce
Healthy Living/Wellness China Rejects Patent Application Of Gilead For $1,000 A Day Hepatitis C Drug Sovaldi by Rhodi Lee
Healthy Living/Wellness Gilead Fights For Hepa C Drug Patents: Activists Concerned About Drug Accessibility by Dianne Depra
Healthy Living/Wellness Expensive Sovaldi drug for hepatitis C still most cost-effective choice for U.S. prisons: Study by Dianne Depra
Healthy Living/Wellness FDA approves Gilead's Harvoni drug: Can we afford the $1125 once-a-day Hepatitis C pill? by Aaron Mamiit
Healthy Living/Wellness Expensive hepatitis C drug Sovaldi to be made cheaper in developing countries by Sumit Passary
Healthy Living/Wellness Hepatitis C drug Sovaldi gets NICE approval despite being pricey by Lori Sandoval
Healthy Living/Wellness Sovaldi hepatitis C drug at $84,000 per treatment course sparks healthcare concerns by Rhodi Lee
Healthy Living/Wellness Study shows promising hep C cure for patients co-infected with HIV by Tina Shah
Healthy Living/Wellness Senate Committee asks Gilead why Hepatitis C drug Sovaldi costs $1000 a pill by James Maynard
Healthy Living/Wellness Senate asks Gilead Sciences to explain itself, high cost of Hep C drug by Tina Shah
Healthy Living/Wellness Sovaldi for hepatitis C from Gilead may kill the virus but can anyone buy it at $84,000? by Rhodi Lee